WebMay 8, 2024 · A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not ...
Did you know?
WebMar 23, 2024 · Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or … WebFeb 26, 2024 · In the phase 1/2 CheckMate-032 study in pts with CTX-R G/GEJ/esophageal cancer (79% ≥ 2 prior Tx lines), NIVO 1 mg/kg + IPI 3 mg/kg had a manageable safety profile and resulted in 24% ORR (40% ORR in pts with PD-L1 + tumors), a median OS of 6.9 mo, and a 35% OS rate at 12 mo (Janjigian Y et al ASCO 2024).
WebMar 31, 2024 · The landmark findings of the CheckMate-577 study, sponsored by Bristol Myers Squibb, represent a major research advancement in the treatment of esophageal (E) and gastroesophageal junction (GEJ) cancers utilizing the PD-1 inhibitor nivolumab as a novel, adjuvant treatment for operable stage II or stage III cancers following neoadjuvant ... WebApr 6, 2024 · In CheckMate 714, the dosage of ipilimumab (1 mg/kg IV every 6 weeks) was based on results from the CheckMate 012 study in advanced NSCLC, 32 in which this dose, in combination with nivolumab 3 mg/kg IV every 2 weeks, was associated with tolerable safety and promising efficacy. While ipilimumab was well tolerated in CheckMate 714, …
WebFeb 26, 2024 · TPS193 Background: Esophageal cancer (EC) is the sixth most common cause of cancer-related death worldwide, with a 5-y survival rate of 5%–8% in pts with metastatic disease. First–line platinum-based doublet chemotherapy (CTX) provides a modest survival benefit in pts with metastatic squamous cell EC (mESCC), with a median … WebJun 5, 2024 · CheckMate 649 met its dual primary endpoints of OS and progression-free survival in the population of patients whose tumours expressed programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) of five or more, with the median OS improving from 11·1 months to 14·4 months from the addition of nivolumab to chemotherapy …
WebCHECKMATE 649 † OPDIVO ® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. 1 CHECKMATE 648 ‡ OPDIVO, in combination with fluoropyrimidine- …
WebSep 22, 2024 · The CheckMate-577 study found that patients who received Opdivo (nivolumab) after chemoradiation and esophagectomy experienced a doubling of the time until recurrence compared to patients who received a placebo. The results were true for patients with both Esophageal Adenocarcinoma and Esophageal Squamous Cell … small paddle wheel river boatWebJun 16, 2024 · LBA4001 Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). We report OS and progression-free survival (PFS) from CheckMate 648, the first global phase III study to evaluate both an immuno-oncology (I-O)/chemo combination and an I-O/I-O combination … small padding pressWebJul 13, 2024 · Immune-checkpoint blockades (ICB) have been added to chemotherapy in advanced esophageal cancers in multiple clinical trials. The KEYNOTE-590 (pembrolizumab), ESCORT-1st (camrelizumab), CheckMate ... small padded envelope sizeWebApr 8, 2024 · Recently, not only chemotherapy, but also chemoradiotherapy, immunotherapy, and chemotherapy plus immunotherapy are performed for advanced esophageal cancer. 1,2,3 The Checkmate-648 trial revealed that both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus … highlight potsdamWebApr 1, 2024 · Methods: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in … highlight powder 邊隻好WebJun 5, 2024 · First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and … small paddle hair brushWebAug 11, 2024 · CheckMate -649 is also evaluating the Opdivo plus Yervoy (ipilimumab) combination compared to chemotherapy in patients with gastric cancer, GEJ cancer or esophageal adenocarcinoma. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. About CheckMate -649 small paddle wheel